ResMed Stock Forum

Morning mooers! It is Finally Friday, April 26th, the market is souring on Mag Seven earnings, even though Personal Consumption Expendetures rose in March.
My name is Kevin Travers, and the beautiful sounds of heavy construction digging foundations for apartments in Jersey City wake me up every morning: the economy is clearly growing.
Here are the morning moovers today:
MOOVERS
The biggest news on the street is $Alphabet-Cearnings that beat and ...

Significant insider selling at ResMed, especially by the Founder, and no insider purchases in the past year may suggest insiders believe shares are overpriced. Despite high insider ownership, the selling warrants caution.

ResMed's impressive performance is due to reinvesting a significant portion of its profits at a high rate of return, leading to substantial earnings growth. Analysts forecast similar growth rates to continue.

ResMed's CEO, Mick Farrell, opines that the market overreacted to the impact of weight-loss drugs on sleep apnea. He suggests that these drugs will complement treatments like ResMed's CPAP systems and that sleep apnea patients using GLP-1s are more motivated to improve their health.

ResMed's high ROCE and ability to reinvest capital at profitable rates suggest potential multi-bagger status. Further research is recommended to understand the current share price value.